Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Urologic Clinics of North America|June 26, 2024
New Therapeutic Horizons for Advanced or Metastatic Penile CancerNicholas Simon, Saad Atiq, Guru Sonpavde, et al.
Urologic Oncology|January 2, 2022
The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancerSaad Atiq, Nathan Hirshman, Afreen Shariff, et al.
Prostate Cancer and Prostatic Diseases|November 10, 2020
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapiesMatthew K Labriola, Saad Atiq, Nathan Hirshman, et al.
Cureus|March 17, 2021
A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and ImmunotherapySaad Atiq, Osman O Atiq, Zainab O Atiq, et al.
Cureus|February 7, 2019
A Unique Case of Severe Anemia Secondary to Copper Deficiency in an Adult PatientSaad Atiq, James M Mobley, Osman O Atiq, et al.
Cancer|August 9, 2025
Top advances of the year: Bladder cancerAndrea B Apolo, Saad Atiq, Andre R Kydd, et al.
Current Opinion in Oncology|March 20, 2025
Antibody-drug conjugates in rare genitourinary tumors: review and perspectivesAndre R Kydd, Md Shahid Sarwar, Saad Atiq, et al.
Future Oncology (London, England)|March 21, 2025
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationaleNicholas Simon, Elias Chandran, Saad Atiq, et al.
Future Oncology (London, England)|May 27, 2025
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationaleElias B A Chandran, Saad Atiq, Nicholas Simon, et al.
Future Oncology (London, England)|June 23, 2025
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationaleAndre R Kydd, Elias Chandran, Nicholas I Simon, et al.
Pageof 1